New hormone therapy shows promise for rare calcium disorder
NCT ID NCT05239221
Summary
This early-stage study tested a new hormone drug called AZP-3601 in healthy volunteers and people with chronic hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. Researchers wanted to understand the drug's safety, how it moves through the body, and its effects on calcium and phosphate levels. The study involved 132 participants and tested single and multiple doses over several months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amolyt Pharma Investigational Site Hungary
Budapest, Hungary
-
PRA-EDS
Groningen, 9728, Netherlands
Conditions
Explore the condition pages connected to this study.